Grufity logoGrufity logo

DXCM

118.11USD+0.08(+0.07%)Market Closed

DexCom Inc

Market Summary

USD118.11+0.08Market Closed
0.07%

DXCM Alerts

DXCM Stock Price

RSI Chart

Valuation

Market Cap

46.7B

Price/Earnings

202.96

Price/Sales

16.71

Price/Cashflow

72.62

MarketCap/EBT

192.18

Price/Sales

Profitability

EBT Margin

8.70%

Return on Equity

12.61%

Return on Assets

4.69%

Fundamentals

Revenue

Revenue (TTM)

2.8B

Revenue Y/Y

18.36%

Revenue Q/Q

10.54%

Earnings

Earnings (TTM)

230.0M

Earnings Y/Y

42.74%

Earnings Q/Q

98.82%

Price Action

52 Week Range

66.89144.96
(Low)(High)

Last 7 days

5.5%

Last 30 days

1.9%

Last 90 days

44.0%

Trailing 12 Months

-15.7%

Financial Health

Current Ratio

3.77

Investor Care

Buy Backs (1Y)

0.37%

Diluted EPS (TTM)

0.55

Peers (Alternatives to DexCom)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-11.88% 44.84%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
14.69% -0.88%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
15.30% -16.82%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
10.69% 8.01%
38.21
3.25
-6.81% -14.96%
61.8B
12.3B
11.14% 17.68%
69.9
5.01
10.11% 51.89%
43.9B
5.4B
8.87% -30.30%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
15.24% 17.79%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
33.98% -14.84%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-8.48% 5.83%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
-16.73% -66.49%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
26.44% 24.39%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
9.49% -7.06%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
17.05% -10.97%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-6.64% -29.40%
-16.43
2.57
-8.79% -175.19%

Financials for DexCom

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue4.5%2,7932,6732,5722,4492,319
Gross Profit2.7%1,8141,7671,7351,6811,607
Operating Expenses1.2%1,5481,5301,4741,4151,238
  S&GA Expenses3.8%940905843811751
  R&D Expenses-3.5%518536544517487
Earnings Before Taxes29.6%243187189174290
Net Income15.2%230200227155561
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-6.1%4,8995,2175,0574,9334,776
  Current Assets-10.8%3,3993,8093,7473,6843,656
    Cash Equivalents-5.1%6987357161,0531,444
  Inventory-8.4%311340342357351
  Net PPE6.3%1,003943857802742
  Goodwill-3.5%2526272724
Liabilities3.8%3,0752,9622,8682,6122,640
  Current Liabilities11.6%901807711721735
Shareholder's Equity-19.1%1,8252,2562,1892,2522,136
  Retained Earnings35.3%388287236139-28.00
  Additional Paid-In Capital1.6%2,0291,9972,1092,322-
Accumulated Depreciation11.4%339304265232203
Shares Outstanding-1.6%386393392388388
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations7.7%643597486443509
  Share Based Compensation2.9%119116115113121
Cashflow From Investing19.6%-823.50-1,023.80-515.70-216.10256
Cashflow From Financing-5120.9%-552.301115106

Risks

What is the probability of a big loss on DXCM?

94.2%


Probability that DexCom stock will be more than 20% underwater in next one year

32.7%


Probability that DexCom stock will be more than 30% underwater in next one year.

29.6%


Probability that DexCom stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does DXCM drawdown profile look like?

Y-axis is the maximum loss one would have experienced if DexCom was unfortunately bought at previous high price.

Returns

Cumulative Returns on DXCM

42.0%


10-Year Cumulative Returns

27.2%


7-Year Cumulative Returns

52.1%


5-Year Cumulative Returns

27.4%


3-Year Cumulative Returns

What are the long-term rolling returns for DXCM?

FIve years rolling returns for DexCom.

Which funds bought or sold DXCM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
ADDED
5.32
91,000
750,000
0.03%
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
864
11,000
0.01%
2022-11-22
CVA Family Office, LLC
ADDED
69.7
20,000
45,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
10,901,000
10,901,000
0.13%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
15.63
82,000
414,000
0.01%
2022-11-21
FourThought Financial, LLC
UNCHANGED
-
-
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-0.35
3,716,000
52,091,000
0.09%
2022-11-21
Parallax Volatility Advisers, L.P.
ADDED
181.95
1,391,000
2,070,000
-%
2022-11-18
Industrial Alliance Investment Management Inc.
ADDED
3.93
216,000
1,971,000
0.06%
2022-11-18
National Pension Service
ADDED
3.94
6,202,000
48,988,000
0.10%

1–10 of 39

Latest Funds Activity

Are funds buying DXCM calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own DXCM

DexCom News

Investor's Business Daily

Market Rally Resilient, But This Battle Continues; What To Do Now | Investor's Business Daily.12 hours ago

DXCM Fair Value

Recent SEC filings of DexCom

View All Filings
Date Filed Form Type Document
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Oct 27, 2022
10-Q
Quarterly Report
Oct 27, 2022
8-K
Current Report
Oct 11, 2022
3
Insider Trading
Sep 12, 2022
4
Insider Trading
Sep 06, 2022
4
Insider Trading
Aug 31, 2022
8-K
Current Report

Latest Insider Trading transactions for DXCM

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-21
Stern Sadie
GIVEN BACK TO IS
-432,910
112.62
-3,844
EVP Chief Human Resources Offi
2022-11-21
Regan Barry J.
GIVEN BACK TO IS
-425,818
112.62
-3,781
EVP Operations
2022-11-21
Sylvain Jereme M
SOLD
-270,288
112.62
-2,400
EVP Chief Financial Officer
2022-11-08
Naganathan Girish
ACQUIRED
31.449
0.001
31,449
EVP Chief Technology Officer
2022-09-08
Selvaraj Shelly Ramasamy
ACQUIRED
4.051
0.001
4,051
SVP Chief Information Officer
2022-09-01
Dolan Matthew Vincent
SOLD
-408.15
81.63
-5
SVP Corporate Strategy-Develop
2022-08-23
Pacelli Steven Robert
SOLD
-84,210
84.21
-1,000
EVP Managing Director Dexcom V
2022-07-25
Pacelli Steven Robert
SOLD
-83,070
83.07
-1,000
EVP Managing Director Dexcom V
2022-06-23
Pacelli Steven Robert
SOLD
-72,550
72.55
-1,000
EVP Managing Director Dexcom V
2022-06-06
Sylvain Jereme M
SOLD
-180,942
301.57
-600
EVP Chief Financial Officer

1–10 of 50

Kevin R. Sayer
6300
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DXCM Income Statement

2022-09-30
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
[1]
Sep. 30, 2022
Sep. 30, 2021
[1]
Income Statement [Abstract]    
Revenue$ 769.6$ 650.2$ 2,094.6$ 1,750.3
Cost of sales275.4203.3752.8542.4
Gross profit494.2446.91,341.81,207.9
Operating expenses:    
Research and development110.3128.8367.9367.3
Amortization of intangible assets1.81.35.72.3
Selling, general and administrative234.6198.5702.4573.1
Total operating expenses346.7328.61,076.0942.7
Operating income147.5118.3265.8265.2
Interest expense(4.6)(4.6)(13.9)(14.1)
Income from equity investments0.00.00.20.0
Interest and other income (expense), net3.3(1.7)5.5(0.7)
Income before income taxes146.2112.0257.6250.4
Income tax expense45.024.78.228.2
Net income$ 101.2$ 87.3[2]$ 249.4$ 222.2[3]
Basic net income per share (USD per share)$ 0.26$ 0.23$ 0.64$ 0.57
Shares used to compute basic net income per share (shares)389.8387.4390.4386.5
Diluted net income per share (USD per share)$ 0.24$ 0.21$ 0.60$ 0.54
Shares used to compute diluted net income per share (shares)425.8430.3428.0427.9
[1]* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.
[2]* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.
[3]* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.

DXCM Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
[1]
Current assets:  
Cash and cash equivalents$ 698.1$ 1,052.6
Short-term marketable securities1,673.81,678.6
Accounts receivable, net564.1514.3
Inventory311.0357.3
Prepaid and other current assets151.581.6
Total current assets3,398.53,684.4
Property and equipment, net1,002.5801.8
Operating lease right-of-use assets73.188.1
Goodwill24.726.5
Intangibles, net24.431.5
Deferred tax assets342.3290.5
Other assets33.710.5
Total assets4,899.24,933.3
Current liabilities:  
Accounts payable and accrued liabilities764.2573.0
Accrued payroll and related expenses112.7125.2
Short-term operating lease liabilities20.920.5
Deferred revenue2.72.1
Total current liabilities900.5720.8
Long-term senior convertible notes1,968.81,981.8
Long-term operating lease liabilities82.198.6
Other long-term liabilities123.390.0
Total liabilities3,074.72,891.2
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at September 30, 2022 and December 31, 20210.00.0
Common stock, $0.001 par value, 800.0 million shares authorized; 393.1 million and 386.2 million shares issued and outstanding, respectively, at September 30, 2022; and 391.4 million and 388.0 million shares issued and outstanding, respectively, at December 31, 20210.40.4
Additional paid-in capital2,072.12,108.7
Accumulated other comprehensive income (loss)(41.1)0.5
Retained earnings388.1138.7
Treasury stock, at cost; 6.9 million shares at September 30, 2022 and 3.4 million shares at December 31, 2021(595.0)(206.2)
Total stockholders’ equity1,824.52,042.1
Total liabilities and stockholders’ equity$ 4,899.2$ 4,933.3
[1]* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.